Clinical Study

Multicenter, Randomized, Double-Blind, Parallel-Group Extension To Study Ac-058B201 To Investigate The Long-Term Safety, Tolerability, And Efficacy Of 10, 20, And 40 Mg/Day Ponesimod, An Oral S1p1 Receptor Agonist, In Patients With Relapsing-Remitting Multiple Sclerosis.

Posted Date: Mar 26, 2014

  • Investigator: Joseph Nicolas
  • Co-Investigator: Lee Gilkerson
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

PURPOSE OF THE STUDY The aims of this study are: • To offer subjects an option to continue treatment with ponesimod, or to initiate treatment with ponesimod if they did not receive active treatment during the core study. • To find out more about the long-term safety and tolerability of ponesimod. • To investigate the long-term effectiveness of ponesimod.

Criteria:

The Subjects All Subjects Who Participated In The Core Study And Completed Their Study Treatment In The Core Study Are Eligible To Enter This Extension Study

Keywords:

Relapsing-Remitting, Neurology, Multiple Sclerosis, Actelion, Null

For More Information:

Alecia Boehl
513-558-0039
alecia.boehl@yahoo.com

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.